VENUS REMEDIES BAGS APPROVAL TO MARKET MEROPENEM, ITS BLOCKBUSTER GENERIC DRUG, IN SPAIN

In an impressive development, Venus Remedies Limited, a prestigious research-based global pharmaceutical organization, has acquired marketing authorization from Spain for its prime generic product, meropenem. The firm achieved this via its German subsidiary, Venus Pharma GmbH, which has received approval for 500mg, 1g, and 2g injections of this indispensable antibiotic.

This is a considerable achievement for Venus Remedies, which has been the largest exporter of meropenem from India in the past three years. The company’s meropenem is a broad-spectrum antibiotic that belongs to the carbapenem class. It is extensively used in intensive care units of hospitals as a final recourse for the treatment of life-threatening infections.

Saransh Chaudhary, President of Global Critical Care at Venus Remedies, emphasized the significance of this authorization. He said, “The marketing approval for this critically important antibiotic has once again proved the company’s world-class manufacturing capabilities and its expertise in developing high-quality products. It will help us strengthen our position in the European market as well.”

The company is planning to introduce the product in December and aims to capture a 10% share in Spain’s meropenem market, valued at $6.34 million. The market size for this product in Europe is around $70.34 million.

Venus Remedies has an impressive track record and has secured more than 120 marketing authorizations for meropenem across the globe, including countries like the UK, France, Germany, Australia, South Africa, UAE, and more.

Additionally, Venus Remedies’ Executive Director, Akshansh Chaudhary, mentioned that they anticipate Venus Pharma GmbH to see a significant increase in turnover in the upcoming quarters, thanks to marketing approvals for meropenem across Europe.

Currently, the company is using 60% of its facilities, which have the capacity to produce 24 million units of meropenem annually on a single-shift basis. With sufficient excess capacity, the company is well-prepared to meet the growing market demands as they expand their marketing network globally.

In conclusion, Venus Remedies has demonstrated its manufacturing prowess and commitment to delivering quality healthcare solutions. With its plans to enter the Spanish market, it continues to solidify its position as a leader in the pharmaceutical industry.

This marks a new chapter in Venus Remedies’ journey, and it is set to continue making a significant impact in global healthcare through its meropenem product.